MORGAN STANLEY PLC/CALL/AMGEN/310/0.1/21.06.24 | Market Closed - Börse Stuttgart 12:02:55 01/06/2024 am IST | ||
| 0.4 EUR | +11.11% |
|
| 1 month | +97.04% | ||
| 3 months | +8.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.4 | +11.11% |
| 30/24/30 | 0.36 | +59.29% |
| 29/24/29 | 0.226 | -60.35% |
| 28/24/28 | 0.57 | -5.00% |
| 27/24/27 | 0.6 | +13.21% |
Delayed Quote Börse Stuttgart
Last update May 01, 2024 at 12:02 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MD7BV6 |
| ISIN | DE000MD7BV66 |
| Date issued | 24/08/2022 |
| Strike | 310 $ |
| Maturity | 21/06/2024 (19 Days) |
| Parity | 10 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.51 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.03 € |
| Spread % | 6.25% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant
